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Background: Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian
cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the
risk of ovarian cancer but not breast cancer in the absence of ovarian cancer. Risk for other cancers has not been
studied.
Methods: To study the role of RAD51C mutations in other common cancer types, we genotyped the Finnish
RAD51C founder mutations c.837 + 1G > A and c.93delG in 1083 prostate cancer patients and 802 colorectal cancer
patients using TaqMan Real-Time PCR.
Results: No RAD51C mutations c.837 + 1G > A or c.93delG were detected among the prostate or colorectal cancer
patients.
Conclusions: The results suggest that the RAD51C mutations do not predispose to prostate or colorectal cancer.
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Mutations in cancer susceptibility genes may predispose
the carriers to different cancer types. The most import-
ant high penetrance breast and ovarian cancer suscepti-
bility genes are BRCA1 and BRCA2 [1] but, in addition
to breast and ovarian cancer, germline mutations in
these genes also increase the risk of prostate cancer [2,3]
and in BRCA2 also of pancreatic cancer [4]. In addition
to the hereditary breast and ovarian cancer syndrome
caused by germline mutations in BRCA1 and BRCA2,
ovarian cancer is also present in the Lynch syndrome
that is caused by germline mutations in DNA mismatch
repair genes and characterized by susceptibility to colo-
rectal cancer [5]. Increased risk of breast cancer is also
present in other rare cancer predisposition syndromes,
namely Li-Fraumeni, Cowden and Peutz-Jeghers syn-
drome and ataxia-telangiectasia, which also predispose
to other cancer types as well [1].* Correspondence: Heli.Nevanlinna@hus.fi
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reproduction in any medium, provided the orBiallelic mutations in BRCA2 and in moderate pene-
trance breast cancer susceptibility genes PALB2 and
BRIP1 cause Fanconi anemia, a chromosomal instability
disorder characterized by developmental abnormalities,
bone marrow failure, and cancer susceptibility, while
heterozygous germline mutations increase the risk of
breast cancer [6]. In addition to breast cancer, heterozy-
gous mutations in PALB2 also increase the risk of pan-
creatic cancer [4] but not prostate cancer [7,8]. In
RAD51C, heterozygous germline mutations have been
identified in breast and ovarian cancer families [9] and a
homozygous missense mutation was found in a Fanconi
anemia like disorder [10]. Following the original report,
we and others have found rare deleterious mutations
among breast and/or ovarian cancer families [11-17] but
quite a few studies have not identified any clearly patho-
genic mutations [18-24]. Indeed, the RAD51C mutations
seem to be very rare. The association with ovarian can-
cer is well-established but whether the mutations also
confer a risk for breast cancer remains controversial.
Meindl et al. [9,25] and Osorio et al. [16] state that
RAD51C mutations predispose to breast and ovarian
cancer whereas Loveday et al. [17] estimated the relativeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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mutation carriers to be 5.88 but no elevated risk for
breast cancer.
We recently sequenced the RAD51C gene in 277
Finnish breast and/or ovarian cancer families and identi-
fied two recurrent deleterious, protein truncating muta-
tions c.837 + 1G > A and c.93delG and subsequently
genotyped the mutations in a large series of breast and
ovarian cancer patients and families [12]. The mutations
significantly increased the risk of ovarian cancer but not
breast cancer in the absence of ovarian cancer family
history, indicating RAD51C as the first moderate pene-
trance susceptibility gene for ovarian cancer. The muta-
tion carrier families shared a common haplotype
indicating a founder effect for the mutations. Moreover,
many of the mutation carriers had family history of vari-
ous cancer types, including for instance colon and pros-
tate cancer. Here we have genotyped the RAD51C
mutations c.837 + 1G > A and c.93delG in 1083 prostate
and 802 colorectal cancer patients to assess the risk for
these cancer types. To our knowledge, the role of
RAD51C mutations in other cancer types than breast
and ovarian cancer has not been studied so far.
Methods
Subjects
The RAD51C mutations c.837 + 1G > A and c.93delG
were genotyped in 1083 Finnish prostate cancer cases
and 802 colorectal cancer cases. The prostate cancer
patients included 894 unselected cases and 189 prostate
cancer families. The unselected cases were collected
from the Pirkanmaa Hospital District. The patients had
been diagnosed with prostate cancer at the urology out-
patient clinic at the Tampere University Hospital be-
tween years 1980 and 2008. All families included two or
more affected members (the youngest affected male
from each family was included in the analysis) and were
collected as previously described [26]. The samples were
genomic DNA isolated from peripheral blood with the
Puregene kit, according to the manufacturer’s instruc-
tions (Gentra Systems, Inc., Minneapolis, MN, USA).
The colorectal cancer patients studied included 509
consecutive patients collected between May 1994 and
April 1996 and 535 consecutive patients collected be-
tween March 1996 and June 1998 at nine large regional
hospitals in southeastern Finland as described previously
[27,28]. DNA was isolated from normal mucosa or blood
by conventional DNA extraction methods. DNA was
available from 802 patients. All the samples were
screened for microsatellite instability (MSI) and the MSI
positive cases were screened for MLH1 and MSH2 muta-
tions. Of the 802 patients, 104 had family background of
colorectal cancer and MLH1 and MSH2 mutations were
identified in 19 cases.This study was carried out according to the Helsinki
declaration with informed consents from the patients
and with permissions from Institutional Review Board of
the Tampere University Hospital, The Ministry of Health
and Social Affairs, National Authority for Medical
Affairs, National Institute for Health and Welfare and
Helsinki University Hospital Ethics Committee.
Genotyping
We used TaqMan Custom Assays and TaqMan Geno-
typing MasterMix (Applied Biosystems, Foster City, CA,
USA) to genotype the c.837 + 1G > A and c.93delG
mutations. PCR was performed in 7500 Fast Real-Time
PCR System or in 9800 Fast Thermal Cycler and geno-
type calling was performed with 7500 Fast Real-Time
PCR System and ABI Prism 7500 SDS v1.4 software
(Applied Biosystems, Foster City, CA, USA).Results and discussion
Most moderate penetrance mutations identified so far,
including mutations in RAD51C, appear to be very rare
with mostly unique mutations in out-bread populations.
This poses considerable challenges for investigating
them in large series of patients with different cancer
types to determine association also with other cancers.
We took here advantage of the RAD51C founder muta-
tions in Finland and genotyped the c.837 + 1G > A and
c.93delG mutations in 1083 prostate and 802 colorectal
cancer patients, including also familial cases. No muta-
tions were detected among the patients.
We previously detected the RAD51C c.837 + 1G > A or
c.93delG mutations in 1.4% of Finnish ovarian cancer
patients (in 1% of unselected ovarian cancer patients and
in 25% of ovarian cancer families) compared to 0.2% in
controls, indicating a significantly increased risk of ovar-
ian cancer with also clinical implications for the carriers
[12]. Moreover, the mutation carrier families were found
to share a common haplotype indicating a shared ances-
try for the families and a founder effect for the muta-
tions in the Finnish population. Founder mutations are
typical for isolated populations, such as the Finnish
population, and they may explain a major fraction of all
mutations in specific genes [29,30]. In the Finnish popu-
lation, strong founder mutations have been detected for
instance in the breast cancer susceptibility genes BRCA1
and BRCA2 [31] as well as in PALB2 [32].
Some of the RAD51C mutation carriers in our previ-
ous study [12] had family history of diverse cancer types
(abdomen, brain, bone marrow, cervical, colon, female
genital, kidney, leukemia, liver, lung, melanoma, pan-
creas, prostate, skin, stomach, tongue, and ventricle) but
unfortunately we did not have available samples for
genotyping of these relatives. Few other studies have also
Pelttari et al. BMC Cancer 2012, 12:552 Page 3 of 4
http://www.biomedcentral.com/1471-2407/12/552identified RAD51C mutation carrier families with diverse
cancer types [9,11,13,15-17]. This prompted us to study
the effect of the mutations also on other common cancer
types besides breast and ovarian cancer by screening of
the founder mutations in an extensive series of prostate
and colorectal cancer cases.
There is a clear genetic component in prostate cancer
susceptibility and several common low-risk genomic loci
for prostate cancer susceptibility have been found but no
high-penetrance genes have been identified [33,34].
Linkage studies have suggested that a prostate cancer
susceptibility gene may be located on chromosome
17q22 [35,36], a region including also the RAD51C
locus, whereas genome-wide association studies
(GWAS) have identified common low risk variants in
17q12 and 17q24 regions [37,38]. Finnish as well as
other Northern European patients have been included
both in the linkage and in the GWA studies [35,36,38].
Several low-risk loci have also been identified for colo-
rectal cancer but 17q22 has not been implicated in colo-
rectal cancer susceptibility [39]. It has been estimated
that 15–30% of colorectal cancer may be hereditary and
approximately one-quarter of the familial cases occur as
part of inherited colorectal tumor syndromes, mainly the
Lynch syndrome caused by mutations in DNA mismatch
repair genes, such as MSH2 and MLH1, and the familial
adenomatous polyposis syndrome caused by mutations
in the APC gene [40]. The absence of the RAD51C
founder mutations among the prostate and colorectal
cancer patients genotyped here suggests that RAD51C
does not contribute to prostate or colorectal cancer pre-
disposition. However, we cannot fully exclude a possible
role of RAD51C as there might be mutation specific
effects on cancer risk. To fully assess the role of
RAD51C in susceptibility to other cancer types, screen-
ing of the whole coding region of the gene in large sam-
ple sets would be needed.Conclusions
In conclusion, we did not detect the Finnish founder
mutations in the RAD51C gene among 1083 prostate
and 802 colorectal cancer patients suggesting that the
RAD51C mutations do not predispose to prostate or
colorectal cancer. These results have clinical value in
assessing the cancer risks associated with RAD51C
mutations in the mutation carrier families.Competing interests
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